- Home
- / Uk & Ireland solutions /
- EU HTA Strategy Support
EU HTA strategy support
Expertise for EU Joint Clinical Assessment (JCA) Preparedness
The introduction of the EU HTA Regulation represents a major shift in how clinical value is assessed across Europe—particularly for high-impact therapies in oncology, rare diseases, and ATMPs. This change brings both challenges and opportunities.
At Kintiga in the UK and Ireland, our experts help you navigate this evolving landscape with regionally grounded, forward-thinking strategies. Our team understands the implications of centralised Joint Clinical Assessments and supports you in aligning early evidence generation with both EU-level and national requirements. With our UK and Ireland based team by your side, as well as our experts across Europe, you’re equipped to lead in this new era of EU HTA.
We offer tailored support across the full JCA lifecycle, including:
- EU HTA Readiness Workshops – Build internal alignment and prepare for regulatory shifts
- Evidence Planning & PICO Simulation – Design data strategies that meet EU and local expectations
- Early HTA Engagement & Scientific Advice – Maximise the impact of early interactions with stakeholders
- Integrated EU HTA Strategy Development – Ensure consistency from planning through execution
- Business Wargaming for UK and Ireland – Test and refine your access strategy under real-world conditions
- Expert JCA Dossier Development – Deliver high-quality submissions with scientific and strategic precision
- Accelerated Dossier Finalisation – Meet tight timelines with focused, deadline-driven support
- Delta Dossier Integration – Translate EU-level outcomes into actionable national access strategies
Our services
Prepare your organisation for the new EU HTA process with our expertly facilitated workshop.
We provide:
- A comprehensive analysis of the general requirements and key success factors of the EU HTA process
- Joint evaluation of the strategic implications for your portfolio and corporate structure
- Facilitated self-assessment tailored to your organisation’s specific functions
- Practical guidance to raise awareness and initiate sustainable tactical measures for effective European market access alignment
We help pharmaceutical companies navigate the complexities of PICO-driven clinical evaluation, ensuring robust preparation for the European Joint Clinical Assessment (JCA) process.
We provide:
- Expert operational assessments and simulations tailored to anticipated PICO schemes (Population, Intervention, Comparator, Outcome)
- Early hypothesis development for final PICO requirements, supporting strategic decision-making for national price negotiations
- Comprehensive gap analysis of your evidence package, formally and strategically identifying areas for improvement
- Recommendations for closing evidence gaps & optimising resource allocation for further evidence generation
- Strategic support to maximise success in national downstream processes across EU member states
Our approach ensures your evidence generation strategy is both efficient and aligned with diverse regulatory expectations, helping you minimise risk and maximise value.
Early scientific and HTA advice is essential for a successful market access strategy. We help you ask the right questions and build a compelling evidence story to optimise your product’s development and reimbursement prospects.
We provide:
- Strategic assessment of the most suitable early advice pathway for your product
- Preparation of comprehensive briefing packages, including initial PICO scope proposals and tactical considerations
- Coordination and submission of JSC and parallel EMA scientific advice requests
- Expert support in preparing for and conducting meetings with HTA bodies and regulatory authorities
- Clear presentation of data and targeted questions to maximise the value of feedback received
- Post-meeting analysis and refinement of your EU market access strategy based on outcomes and recommendations
Partner with us to ensure your engagement with HTA and regulatory authorities is expertly managed, paving the way for successful product development and market entry.
Navigating the complexities of EU Health Technology Assessment (HTA) requires a forward-thinking, integrated strategy. We support you in achieving optimal reimbursement outcomes while ensuring broad patient access across Europe.
We provide:
- Comprehensive development and implementation of tailored EU HTA strategies
- Integration of national price analyses into the overall EU HTA approach
- Roadmap creation for actionable steps to maximise success before and during the EU HTA process
- Strategic scenario planning and operational support for tactical execution
- Ongoing partnership and guidance throughout every stage of the EU HTA journey up until the national price negotiations
Prepare your team for the EU HTA process with our immersive, hands-on business wargaming training. We bridge the gap between theory and practice, enabling participants to experience and master real-world decision-making before the actual Joint Clinical Assessment (JCA) procedure.
We provide:
- Realistic, scenario-based simulations tailored to the EU HTA environment
- Role-playing exercises that mirror actual stakeholder interactions and decision-making pressures
- Immediate feedback on choices and strategies to reinforce learning
- Development of effective communication and information-flow routines
- Enhanced understanding and retention of the EU HTA framework
- Practical preparation for the real JCA procedure, ensuring your team is ready to perform at its best
Delivering high-quality, strategically structured JCA dossiers within tight deadlines.
We provide a comprehensive, AI-supported & agile approach to the creation and management of European JCA dossiers, ensuring efficiency, accuracy, and compliance with all regulatory requirements.
Our services include:
- Modular, technology-supported dossier writing and quality control processes
- Semi-automated table textualisation and interpretation aligned with JCA qualitative standards
- Advanced large document handling and management using LaTeX-based text editing tools
- Expert guidance for the timely and formally correct compilation of European JCA dossiers and submission files
With extensive experience in the successful delivery of diverse (especially German) HTA dossiers, we are your ideal partner for navigating the complexities of the European JCA process.
Specialist intervention for teams under pressure to finalise their JCA dossier on time.
We provide immediate, high-impact support for late-stage JCA dossier projects, ensuring you meet regulatory requirements and submission deadlines—even when time is critically short.
Our services include:
- Intensive dossier review and gap analysis to identify and address critical issues
- Rapid data collation, integration, formatting and description in line with JCA standards
- Fast-track AI-supported writing and quality control for accelerated turnaround
- Streamlined document management for large, complex documents using LaTeX-based text editing tools
- Expert troubleshooting of methodological and technical challenges
- Direct guidance on compliance with the latest European JCA requirements
- Proven management in critical situations with a track record of delivering dossiers under tight timelines
Rely on our experience and advanced tools to bring your dossier across the finish line—on time and in full compliance.
Achieve seamless market access by expertly navigating both European and national requirements. Our local expertise ensures your value story is compelling and compliant at every level.
We provide:
- Strategic guidance to align European and national HTA and pricing strategies
- Preparation of comprehensive national dossiers tailored to local requirements on the basis of JCA pre-work
- In-line integration of cost-effectiveness analyses and additional evidence as required
- Expert advice on positioning your therapy for national appraisal and reimbursement
- Ongoing support to ensure your dossier remains the foundation for successful market entry
Delivering impact through excellence
Results speak louder than words. At Kintiga, our track record of success demonstrates our ability to deliver impactful market access strategies that align with your ambitions.
Let’s have a chat
We pride ourselves to have a personal relationship with our network of stakeholders, opinion leaders and clients, and we would love to get to know you as well. Feel free to reach out for a chat.
Julia Sus
Director, Market Access, UK
Claire Blaney
Director Market Access & Pricing Strategy Ireland
Priscila Mazzola
Director, Head of Value Communication in Value Communication
Ben Hendry
Director, Business Development UK & Ireland
Featured case studies
Delivering a Successful SMC Re‑Submission Through Strategic Alignment and Rapid Cross‑Functional Execution
Faster, Fairer, Broader: What NICE’s 2025–26 Annual Report Means for Market Access
NICE’s New Rulebook for Obesity Health Economics: What PMG50 Means for Modellers
PMI Pharma Summit
NICE Conference 2026
Poster Presentation: Increased trends of self-optimised submissions to NICE (HTA 199)
Our expertise:
UK and Ireland Access Consultancy
Our UK and Ireland team provide tailored strategic guidance and end-to-end support across development, launch, and lifecycle management, aligned with NICE, SMC, AWMSG, and NCPE pathways and evolving HTA expectations.
UK and Ireland Market Access Pathways
Success starts with a clear launch pathway. Kintiga offers UK and Ireland expertise, supporting NICE, SMC, AWMSG, and NCPE submissions with strong evidence alignment, payer negotiation, and stakeholder engagement to drive positive outcomes.
EU HTA Strategy Support
With extensive NICE submission experience, Kintiga is well positioned to support Joint Clinical Assessments, offering integrated solutions from JSC advice to JCA reporting for successful EU HTA outcomes.
Health Economics and Outcomes Research
Our Health Economists build and adapt economic models for the UK and Ireland, integrating local data, comparators, and care pathways. We also develop early pricing and access models to guide investment and evidence strategies aligned with payer expectations.
Pricing Strategy
Kintiga analyses pricing landscapes and benchmarks competitors to shape early pricing strategies. We integrate value messaging and design long-term frameworks like risk-sharing and managed entry agreements to ensure sustainable UK and Ireland market access.
Policy and Systems Navigation
Kintiga monitors policy changes across NHSE, DoH, HSE, and regional bodies to assess their impact on your product. We provide strategic engagement with key institutions and support managed access, conditional reimbursement, and policy initiatives to optimise market entry and sustainability.
Contact us
Ready to unlock your product’s potential in Europe’s complex healthcare landscape? Contact Kintiga today to discover how our market access strategy expertise can drive measurable impact for your product.
